AzTrials
AzTrials

Computed Tomography AngiographyDEPICT CTANCT04491513

Detection of Proximal Coronary Artery Disease in the Work-up for Transcatheter Aortic Valve Implantation Using CTA (From the DEPICT CTA Database)

An observational study of Computed Tomography Angiography and Coronary Artery Disease, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: Computed tomography angiography (CTA) is already used in the work-up for transcatheter aortic valve implantation (TAVI) and could partially replace invasive coronary angiography (CAG) to rule out proximal coronary lesions. Read more about this study

Who is it for?
Any age
What is being tested?
Computed tomography angiography
How many people
1,060 participants
Where
1 siteNetherlands
Study dates
1 Oct 2019to 1 Jul 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Child, Adult, Older adult

Study population: Patients in the work-up for TAVI

Who may be able to join

  • Patients in the work-up for TAVI

Who cannot join

  • inability to undergo CTA

Trial locations and contacts

1 site in 1 country.

Netherlands1 site
  • Amsterdam UMC

    Amsterdam, North Holland, 1105AZ

Other trials in Netherlands

About this study

Background: Computed tomography angiography (CTA) is already used in the work-up for transcatheter aortic valve implantation (TAVI) and could partially replace invasive coronary angiography (CAG) to rule out proximal coronary lesions.

Objectives: To assess the diagnostic accuracy and yield of pre-TAVI CTA to detect coronary lesions (≥50% DS and ≥70% DS) in the proximal coronary segments on a per-patient and a per-segment level.

Methods: The DEPICT CTA database consists of individual patient data of four studies that analysed the diagnostic accuracy of pre-TAVI CTA to detect coronary lesions. For this analysis, diagnostic accuracy was assessed in the left main and the three proximal coronary segments.

Read the detailed description

Methods Objectives To assess the diagnostic accuracy and yield of pre-TAVI CTA to detect coronary lesions (≥50% DS and ≥70% DS) in the proximal coronary segments on a per-patient and a per-segment level. The secondary objective was to perform a subgroup analysis of the individual included studies and to assess the influence of atrial fibrillation and heart rate on the diagnostic accuracy.

Literature search and study selection Studies were selected from our previous systematic review and meta-analysis on the diagnostic accuracy of CTA for the detection of significant CAD in TAVI work-up [4]. These studies were supplemented with studies that were retrieved by an updated literature search in OVID MEDLINE (including Epub Ahead of Print, In-Process \& Other Non-Indexed Citations) and OVID EMBASE from January 1, 1946 to October 01, 2019. Studies were excluded if they were not reporting original data of patients who received both pre-procedural multi-detector computed tomography (MDCT) and CAG for the evaluation of CAD in the work-up of TAVI. The authors of 8 studies were approached to jointly perform a meta-analysis of individual patient data. The authors of 4 studies could accommodate the data for a per segment analysis [5-8]. The methodological quality of the included studies was assessed using the modified Quality Assessment of Studies of Diagnostic Accuracy Included in Systematic Reviews-2 criteria (QUADAS-2) [9].

Data collection The data sets included patient characteristics regarding age, sex, body mass index (BMI) and the heart rate during CT-scan. Information about co-morbidities included the presence of diabetes mellitus, atrial fibrillation, hypercholesterolemia, peripheral atrial disease, hypertension, a history of smoking, presence of CAD and a history of PCI or coronary artery bypass grafting. Technical CT scanner information included scanner type, number of detector rows, number of slices, detector width, CT scanner rotation time, scan protocol and settings (tube voltage and tube current), contrast agent type and volume, dose length product, and nitroglycerine use.

The coronary segments were categorized in three categories: lesions <50% DS, lesion ≥50-70% DS or lesions ≥70% DS), according to the 18-segment coronary model of the Society of Cardiovascular Computed Tomography or the American Heart Association modified 15-segment model [10,11]. All studies used a cut-off of ≥50% diameter stenosis to determine the presence of obstructive CAD. Three out of four studies also used a cut-off value of ≥70% DS [5,7,8], which were used for an additional analysis of the diagnostic accuracy to detect ≥70% DS proximal obstructive coronary lesions. If a segment had poor image quality or severe motion artefacts, it was labelled as non-diagnostic.

Statistical analysis Data analysis was performed using the statistical software R version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria). Continuous variables were presented as means with standard deviations (SD). The distribution of continuous variables was tested with the Shapiro-Wilk test. Categorical variables were presented as frequencies and percentages. The prevalence of proximal lesions of ≥50% DS and of ≥70% DS was computed from the measurements with invasive CAG, because revascularization with PCI is only considered in case of a proximal ≥70% DS lesion.(ref ESC guideline) Diagnostic accuracy of pre-TAVI CTA, as compared to pre-TAVI CAG, was defined as the sensitivity, specificity, positive - (PPV) and negative predictive value (NPV) and was derived from the number of true positives (TP), true negatives (TN), false positives (TP) and false negatives (FN). The analysis of the primary endpoint was performed on a per-patient and per-segment level. Diagnostic accuracy was computed for CTA to detect obstructive proximal coronary lesions of more than 50% DS and also of ≥70% DS lesions in a subgroup of patients were the data was available. All non-diagnostic segments were considered as abnormal tests and were labelled as if there was a lesion. For the per-patient analysis of diagnostic accuracy, patients were regarded as having proximal obstructive lesions if there was a minimum of one non-diagnostic segment. Diagnostic yield was defined as the number of patients that would not need an invasive CAG if pre-TAVI CTA was used as a gatekeeper to rule out obstructive proximal lesions and was derived from the sum of the negatives (TN + FN). For the subgroup analysis, we analysed the diagnostic accuracy in the individual included studies and assessed the diagnostic accuracy in the subgroups with atrial fibrillation and a heart rate <70 and ≥70 b/min. The diagnostic accuracy in the individual studies and the subgroups was assessed on a per-patient level for lesions ≥50% DS.

Being tested
Computed tomography angiography
Keywords
Computed tomography angiography, coronary angriography, Aortic Valve Disease, Transcatheter aortic valve implantation
Medical subject headings
Coronary Artery Disease, Aortic Valve Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Computed tomography angiographyDiagnostic test

    Computed tomography angiography for the detection of proximal coronary lesions in patients in the work-up for TAVI

Study groups in NCT04491513
Study groupRoleWhat they receive
Overall cohortPateints that underwent both CTA and CAG in the work-up for TAVI
Receives: Diagnostic Test: Computed tomography angiography

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Diagnostic accuracy and yield of pre-TAVI CTA to detect coronary lesions (≥50% DS and ≥70% DS) in the proximal coronary segments on a per-patient and a per-segment level.

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jul 2020
  2. Study start1 Oct 2019
  3. Primary completion1 Jul 2020
  4. Study completion1 Jul 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Retrospective
Enrolment
1,060 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04491513
Sponsor's protocol ID
Amsterdam UMC
Acronym
DEPICT CTA
Status last verified
Jul 2020
First submitted
26 Jul 2020
Last updated
29 Jul 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Individual patient data will be made available during or after publication of initial outcome paper

Publications

  • Andreini D, Pontone G, Mushtaq S, Bartorelli AL, Ballerini G, Bertella E, Segurini C, Conte E, Annoni A, Baggiano A, Formenti A, Fusini L, Tamborini G, Alamanni F, Fiorentini C, Pepi M. Diagnostic accuracy of multidetector computed tomography coronary angiography in 325 consecutive patients referred for transcatheter aortic valve replacement. Am Heart J. 2014 Sep;168(3):332-9. doi: 10.1016/j.ahj.2014.04.022. Epub 2014 Jun 9.

    PubMed 25173545
  • Opolski MP, Kim WK, Liebetrau C, Walther C, Blumenstein J, Gaede L, Kempfert J, Van Linden A, Walther T, Hamm CW, Mollmann H. Diagnostic accuracy of computed tomography angiography for the detection of coronary artery disease in patients referred for transcatheter aortic valve implantation. Clin Res Cardiol. 2015 Jun;104(6):471-80. doi: 10.1007/s00392-014-0806-z. Epub 2015 Jan 6.

    PubMed 25559245
  • Hamdan A, Wellnhofer E, Konen E, Kelle S, Goitein O, Andrada B, Raanani E, Segev A, Barbash I, Klempfner R, Goldenberg I, Guetta V. Coronary CT angiography for the detection of coronary artery stenosis in patients referred for transcatheter aortic valve replacement. J Cardiovasc Comput Tomogr. 2015 Jan-Feb;9(1):31-41. doi: 10.1016/j.jcct.2014.11.008. Epub 2014 Dec 3.

    PubMed 25576406
  • Rossi A, De Cecco CN, Kennon SRO, Zou L, Meinel FG, Toscano W, Segreto S, Achenbach S, Hausleiter J, Schoepf UJ, Pugliese F. CT angiography to evaluate coronary artery disease and revascularization requirement before trans-catheter aortic valve replacement. J Cardiovasc Comput Tomogr. 2017 Sep-Oct;11(5):338-346. doi: 10.1016/j.jcct.2017.06.001. Epub 2017 Jun 22.

    PubMed 28662835

Questions about this trial

What is this clinical trial studying?

An observational study of Computed Tomography Angiography and Coronary Artery Disease, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Diagnostic accuracy and yield of pre-TAVI CTA to detect coronary lesions (≥50% DS and ≥70% DS) in the proximal coronary segments on a per-patient and a per-segment level. (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04491513, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in